Alpha lactalbumin is a whey protein, found among other places, in mothers milk. It has recently been in the news as the primary protein used in the search for a cure for breast cancer.

For the last eight years, Dr. Vincent Tuohy, at the Cleveland Clinic, has been searching for a vacine for breast cancer. Dr. Tuohy discovered that mice injected with the vaccine, based on Alpha lactalbumin, did not develop breast tumors, while 100 percent of the mice that were not vacinated, had breast tumors.

The vacine also seems to inhibit the growth of pre-existing tumors.

In an interview he also states that "There's nothing fancy about it. We're vaccinating against something that isn't there unless you have tumors, so it shouldn't harm you. And it should kill the tumors,".

The main part of the vaccine, a protein called Alpha lactalbumin found in lactating breasts, is also found in breast tumors, but not in healthy breasts. It is suggested that women who are finished breast feeding, would recieve the vaccine thus boosting their own immune systems and supplying the means to kill off cancerous cells while not damaging healthy ones.

"We think that breast cancer is a completely preventable disease in the same way that polio is completely preventable," Dr. Tuohy says.

This sort of research gives hope to anyone who has, or knows of anyone with breast cancer. To say nothing of outright prevention. In 2009, The American cancer society estimates that there was 192,370 new cases of invasive breast cancer and 40,170 deaths from breast cancer.

(c) 2010 Alphalactalbumin.com

Use of this article is forbidden without express permission from the author.

Breast cancer cells could hold key
TESTING breast cancer cells to see how closely they resemble stem cells could identify women with the most aggressive disease, new research has suggested.Read More...

Agreement on best estimates of breast cancer overdiagnosis urgently needed to inform women
More than any other debate about overdiagnosis, the discussion of breast cancer has spilt from the pages of the specialist medical press into the public domain, argues a public health expert, stating that changing screening policy "should be based on demonstrated ability to achieve equivalent benefit to harm ratios and not on the assumption that increased detection will achieve a net benefit."Read More...

Breast cancer: Scientists can now detect most aggressive forms of killer disease
Scientists have discovered a way to detect which women with breast cancer have the most aggressive type. More than 50,000 are diagnosed with breast cancer every year in the UK, and 12,000 will die from it.Read More...

New test to target breast cancer
Testing breast cancer cells for how closely they resemble stem cells could identify women with the most aggressive disease, new research has suggested.Read More...

GTx Provides Corporate Update and Reports Fourth Quarter and Year-End 2014 Financial Results
GTx, Inc. today reported financial results for the fourth quarter and year ended December 31, 2014, and highlighted recent accomplishments and upcoming milestones. The Company remains focused on targeting the androgen receptor in women with advanced breast cancer using enobosarm, the Company s oral nonsteroidal selective androgen receptor modulator.Read More...

Novel Approach Helps Prevent Early Menopause in Breast Cancer Patients, Study Finds
Early menopause can be prevented and fertility may be preserved in young women with early stage breast cancer, according to a study published today in The New England Journal of Medicine.Read More...

MacroGenics Provides Update on Corporate Progress and 2014 Financial Results
-- Four oncology molecules in clinical development, including two bi-specific DART(R) molecules -- Margetuximab Phase 3 SOPHIA study in metastatic breast cancer to initiate 3Q 2015 -- Cash runway extends ...Read More...

Press Release
ANDOVER Massachusetts March 5 2015 /PRNewswire/ -- Royal Philips (NYSE: PHG AEX: PHIA) today announced its collaboration with the University of California Irvine to explore how spectral breast imaging can improve breast density measurement potentially aiding clinicians in more accurately gauging breast cancer risks and monitoring changes over time.Read More...

Agendia s BluePrint Molecular Subtyping Assay Highlighted at the 32nd Annual Miami Breast Cancer Conference
Agendia, a leading molecular diagnostics company that develops and markets genomic diagnostic products, said new data from an ongoing study indicates the BluePrint functional moleRead More...

Laser treatment study a first for NZ
Otago University s School of Physiotherapy will run the first clinical evaluation of laser treatment for lymphoedema in New Zealand, on behalf of the NZ Breast Cancer Foundation.Read More...